Facilitating the research of numerous nationally and internationally recognized scientists, in over sixty labs across British Columbia, to improve cancer care.

BC Cancer Research strives to improve the lives of patients through the integration of basic biomedical research, genomics, clinical trials, health services research, cancer surveillance, population health, and the development of innovative new technology, programs, and interventions. Organized through departments and programs with various themes, BC Cancer supports groundbreaking cancer research and personalized care approaches through world-class facilities and platforms including genomics, bioinformatics, imaging, drug development and tissue banking.

Our Research

The success of BC Cancer is driven by the people and their passion to reduce the impact of cancer on people and society. Our 2022 Research Report showcases how BC Cancer continues to be internationally recognized for our excellence in cancer research and its integrated model of cancer planning and care. 

Read the 2022 BC Cancer Research Report. 

News & Events

Reflections from our Inaugural GSC Collaborator Forum 2024

Since our founding in 1999, the GSC has sequenced over 6,000,000,000,000,000 bases, sequenced the genomes of more than 350 species, and facilitated ground-breaking discoveries in cancer research. On October 22, 2024, we hosted our inaugural Collaborator Forum, bringing together a vibrant mix of researchers, industry experts, and both old and new colleagues to celebrate decades of collaboration and to foster new scientific partnerships.

Registration Now Open for Inaugural GSC Collaborator Forum

Registrations are now open for the Inaugural GSC Collaborator Forum on Tuesday, October 22nd!

An exciting line-up of invited speakers will share insights into topics ranging from plant genomes to the latest advances in cancer research. Join us for a day of sharing technical expertise and networking with Vancouver’s vibrant genomic research community!

Register here: https://www.eventbrite.com/e/gsc-collaborator-forum-tickets-1005351151357?aff=oddtdtcreator

Research Recovery Resources

BC Cancer Research is taking a gradual and careful approach to re-opening research activities to protect our staff, patients and communities.

Access our COVID-19 recovery resources.

Our Strategic Plan

Our Strategic Plan outlines our direction to strengthen our research capabilities and collaboration with departments and partners to improve our ability to generate knowledge, enhance the impact of our research, and support innovation in clinical care.  

Read the BC Cancer Research Strategic Plan.

Facilitating research excellence through management of day-to-day operations.

Office of Research Administration

Conducting research to improve the prevention, detection and treatment of cancer.

Cancer Control Research

Developing and deploying genomics technologies and services in support of cancer and life sciences research.

Genome Sciences Centre

Making novel discoveries in the biology underlying normal development and cancer progression.

Terry Fox Laboratory

Characterising the molecular changes that underpin the progression and pathogenesis of cancer.

Molecular Oncology

Researching the optical, radiobiological and genetic properties of cancer.

Integrative Oncology

Improving patient outcomes by gaining a deeper understanding of lymphoma biology and progression, for use in clinical applications.

Lymphoid Cancer Research

Defining better intervention strategies for individuals diagnosed with aggressive cancers.

Experimental Therapeutics

Clinical Research

Harnessing the immune system to detect and treat cancer.

Deeley Research Centre

The Nursing and Allied Health Research and Knowledge Translation department promotes innovation and excellence in interprofessional research and knowledge mobilization to drive evidence-informed improvements in care, better patient outcomes and increased system performance.

Nursing and Allied Health Research and Knowledge Translation

Publications

TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma

Nature Medicine, 2020
Daisuke Ennishi, Shannon Healy, Ali Bashashati, Saeed Saberi, Christoffer Hother, Anja Mottok, Fong Chun Chan, Lauren Chong, Libin Abraham, Robert Kridel, Merrill Boyle, Barbara Meissner, Tomohiro Aoki, Katsuyoshi Takata, Bruce W Woolcock, Elena Viganò, Michael Gold, Laurie L Molday, Robert S Molday, Adele Telenius, Michael Y Li, Nicole Wretham, Nancy Dos Santos, Mark Wong, Natasja N Viller, Robert A Uger, Gerben Duns, Abigail Baticados, Angel Madero, Brianna N Bristow, Pedro Farinha, Graham W Slack, Susana Ben-Neriah, Daniel Lai, Allen W Zhang, Sohrab Salehi, Hennady P Shulha, Derek S Chiu, Sara Mostafavi, Alina S Gerrie, Da Wei Huang, Christopher Rushton, Diego Villa, Laurie H Sehn, Kerry J Savage, Andrew J Mungall, Andrew P Weng, Marcel B Bally, Ryan D Morin, Gabriela V Cohen Freue, Louis M Staudt, Joseph M Connors, Marco A Marra, Sohrab P Shah, Randy D Gascoyne, David W Scott, Christian Steidl
Learn More
Back to top